Status:
WITHDRAWN
CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19
Lead Sponsor:
Pentracor GmbH
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The 'CAPMYKCO' study is a randomized controlled, open-label, single center proof of concept trial. The aim of this study is to evaluate whether a CRP-apheresis in addition to the current standard ther...
Detailed Description
The prognostic value of C-reactive protein (CRP) in assessing disease progression in COVID-19 is well known: The steeper the CRP rise in the days after infection and the higher the CRP concentration a...
Eligibility Criteria
Inclusion
- Confirmed SARS CoV-2 infection (PCR-test)
- Oxygen therapy (maximum 'high-flow' therapy)
- CRP plasma concentration ≥ 50 mg/l and/or
- CRP increase ≥ 15 mg/l within 24 h after admission.
- Completed informed consent and written informed consent.
- Legal capacity
Exclusion
- Age \< 18 years
- Pregnancy / lactation period
- Invasive, mechanical ventilation
- Extracorporeal membrane oxygenation (ECMO)
- Participation in other interventional trials
- Extracorporeal membrane oxygenation (ECMO) support
- Participation in other interventional trials
Key Trial Info
Start Date :
May 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04898062
Start Date
May 5 2021
End Date
March 31 2023
Last Update
January 19 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
West-German Heart and Vascular Center, University Duisburg-Essen
Essen, North Rhine-Westphalia, Germany, 45122
2
Gemeinschaftskrankenhaus Havelhöhe gGmbH
Berlin, Germany, 14089
3
Universitätsklinikum des Saarlandes
Homburg, Germany, 66421
4
Klinikverbund Allgäu gGmbH
Kempten, Germany, 87439